Making prostate-specific antigen testing more effective

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 3, 2006, Pages 177-179

  Catalona, William J ^a   Loeb, Stacy ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EDITORIAL; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33646183006     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.09.001     Document Type: Editorial

References (21)

1. American Cancer Society. Cancer facts & figures. Available at: www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed October 27, 2005.
2. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2002/. November 2004 SEER data submission, posted to the SEER website 2005. Accessed October 27, 2005.
3. Fang J., Metter E.J., Landis P., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer. Results from the Baltimore Longitudinal Study of Aging. Urology 58 (2001) 411-416
4. Loeb S., Roehl K.A., Antenor J.A.V., et al. Baseline PSA compared with median for age group as predictor of pathologic tumor features in men <60 years of age. J Urol 173 Suppl 4 (2005) 145
5. Kundu S.D., Grubb R.L., Roehl K.A., et al. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol 173 (2005) 1116-1120
6. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948-954
7. Freedland S.J., Aronson W.J., Kane C.K., et al. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 101 (2004) 748-753
8. Krumholtz J.S., Carvalhal G.F., Ramos C.G., et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60 (2002) 469-7
9. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
10. Ohori M., Wheeler T.M., Dunn J.K., et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714-1720
11. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
12. Schroder F.H., van der Cruijsen-Koeter I., de Koning H.J., et al. Prostate cancer detection at low prostate specific antigen. J Urol 163 (2000) 806-812
13. Raaijmakers R., Blijenberg B.G., Finlay J.A., et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml. Value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 (2004) 2245-2249
14. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer. What happened in the last 20 years?. J Urol 172 (2004) 1297-1301
15. Ramos C.G., Roehl K.A., Antenor J.A., et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 172 (2004) 137-140
16. Mitchell R.E., Shah J.B., Desai M., et al. Preoperative PSA lost the ability to predict biochemical failure after radical retropubic prostatectomy?. J Urol 173 Suppl 4 (2005) 256 [Abstract 948]
17. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
18. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
19. Fang J., Metter E.J., Landis P., et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59 (2002) 889-893
20. Berger A.P., Diebl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer. Assessment of prostate cancer risk. J Urol 173 Suppl 4 (2005) 402
21. Yu X., Han M., Gashti S.N., et al. Comparison of different methods for calculating PSA velocity. Importance of time interval prior to diagnosis of prostate cancer. J Urol 173 Suppl (2005) 469